Omega Therapeutics (NASDAQ:OMGA – Get Rating) and PharmaCyte Biotech (OTCMKTS:PMCBD – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.

Valuation & Earnings

This table compares Omega Therapeutics and PharmaCyte Biotech's gross revenue, earnings per share (EPS) and valuation.

PharmaCyte Biotech has lower revenue, but higher earnings than Omega Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Omega Therapeutics and PharmaCyte Biotech, as reported by MarketBeat.

Omega Therapeutics currently has a consensus target price of $9.60, indicating a potential upside of 33.52%. Given Omega Therapeutics' higher probable upside, equities research analysts plainly believe Omega Therapeutics is more favorable than PharmaCyte Biotech.

Insider & Institutional Ownership

88.7% of Omega Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PharmaCyte Biotech shares are held by institutional investors. 60.0% of Omega Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Omega Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.

Profitability

This table compares Omega Therapeutics and PharmaCyte Biotech's net margins, return on equity and return on assets.

Summary

Omega Therapeutics beats PharmaCyte Biotech on 6 of the 10 factors compared between the two stocks.

About Omega Therapeutics

(Get Rating)

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, as well as the mechanism that controls gene expression and aspect of an organism's life. The company's platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a range without altering native nucleic acid sequences. Its modular and programmable mRNA medicines, and Omega Epigenomic Controllers are designed to target specific epigenomic loci within insulated genomic domains from genome-wide DNA-sequences with single or multiple genes to treat and cure diseases through Precision Genomic Control. The company is advancing a pipeline of development candidates covering a range of disease areas, including oncology, regenerative medicine, multigenic diseases, and select monogenic diseases. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

About PharmaCyte Biotech

(Get Rating)

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

Receive News & Ratings for Omega Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.